Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

12.44
-0.2900-2.28%
Post-market: 12.620.1800+1.45%19:33 EDT
Volume:48.87K
Turnover:610.23K
Market Cap:63.48M
PE:-5.19
High:12.72
Open:12.72
Low:12.10
Close:12.73
52wk High:16.93
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:1.81
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-123.84%
PB:-4.53
PE(LYR):-4.25

Loading ...

MiNK Therapeutics Highlights Phase 2 Trial Testing agenT-797 with Botensilimab and Balstilimab in MSS Colorectal Cancer Liver Metastases

Reuters
·
Oct 02

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

GlobeNewswire
·
Oct 02

MiNK selected for ARPA-H-Funded initiative to advance room-temp cell therapy

TIPRANKS
·
Sep 30

MiNK Therapeutics iNKT Platform Joins ARPA-H-Funded Room-Temperature Cell Therapy Program

Reuters
·
Sep 30

Mink Therapeutics - Arpa-H Commits up to $87 Mln to Four-Year Boss Program

THOMSON REUTERS
·
Sep 30

Mink Therapeutics Selected for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy

THOMSON REUTERS
·
Sep 30

MiNK Therapeutics Q2 Loss Narrows on Expense Discipline

Reuters
·
Aug 13

MiNK Therapeutics Q2 EPS $(0.62) Misses $(0.60) Estimate

Benzinga Earnings
·
Aug 13

MiNK Therapeutics Q2 EPS USD -0.62

Reuters
·
Aug 13

Mink Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury

THOMSON REUTERS
·
Aug 13

Press Release: MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Dow Jones
·
Aug 13

Mink Therapeutics Inc Expected to Post a Loss of 60 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Mink Therapeutics - First Agent-797 Patients Alive and Afebrile at Day 28 with Improved Oxygenation

THOMSON REUTERS
·
Aug 07

Mink Therapeutics - no Major Serious Adverse Events Attributed to Agent-797 in First Patients

THOMSON REUTERS
·
Aug 07

Mink Therapeutics - Enrollment Continues in Lviv with U.S. Sites Opening; Additional Data Expected Early 2027

THOMSON REUTERS
·
Aug 07

MiNK Therapeutics Reports Early Phase 2 Data for agenT-797 in Severe Hypoxemic Pneumonia Trial

Reuters
·
Aug 07

Mink Therapeutics to Report Q2 Results, Host Conference Call and Webcast

Reuters
·
Aug 06

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

GlobeNewswire
·
Aug 06

MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch

TIPRANKS
·
Jun 27

MiNK Therapeutics Stockholders Back Directors, Ratify Auditor

TIPRANKS
·
Jun 23